Syros Pharmaceuticals is a new company that is harnessing developments in genetics control to improve the treatment of major life threatening diseases such as cancer. It recently announced the completion of a US$30 million Series A financing.
The financing round was led by co-founder ARCH Venture Partners and Flagship Ventures. Syros would be utilizing the capital to advance the discovery and development of gene control medication and therapies. These are what are known as Super Enahncers.
Nancy Simonian MD would be leading the company as CEO. With her proven experience in the biotechnological field, she has guided the development of revolutionary treatments for patients with diseases such as multiple sclerosis, multiple myeloma and mantle cell lymphoma.
Currently, Syros has existing and standing exclusive worldwide licensing agreements with leading cancer research institutions such as the Whitehead Institute and the Dana Farber Cancer Insitute. The licenses held by Syros include lead scientific components such as Super-Enhancer methodologies and treatments.
Join the Conversation